224 related articles for article (PubMed ID: 21098317)
1. Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia.
Steensma DP; Sloan JA; Dakhil SR; Dalton R; Kahanic SP; Prager DJ; Stella PJ; Rowland KM; Novotny PJ; Loprinzi CL
J Clin Oncol; 2011 Jan; 29(1):97-105. PubMed ID: 21098317
[TBL] [Abstract][Full Text] [Related]
2. Oral sucrosomial iron versus intravenous iron in anemic cancer patients without iron deficiency receiving darbepoetin alfa: a pilot study.
Mafodda A; Giuffrida D; Prestifilippo A; Azzarello D; Giannicola R; Mare M; Maisano R
Support Care Cancer; 2017 Sep; 25(9):2779-2786. PubMed ID: 28391437
[TBL] [Abstract][Full Text] [Related]
3. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia.
Bastit L; Vandebroek A; Altintas S; Gaede B; Pintér T; Suto TS; Mossman TW; Smith KE; Vansteenkiste JF
J Clin Oncol; 2008 Apr; 26(10):1611-8. PubMed ID: 18375890
[TBL] [Abstract][Full Text] [Related]
4. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy.
Henry DH; Dahl NV; Auerbach M; Tchekmedyian S; Laufman LR
Oncologist; 2007 Feb; 12(2):231-42. PubMed ID: 17296819
[TBL] [Abstract][Full Text] [Related]
5. Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha.
Pedrazzoli P; Farris A; Del Prete S; Del Gaizo F; Ferrari D; Bianchessi C; Colucci G; Desogus A; Gamucci T; Pappalardo A; Fornarini G; Pozzi P; Fabi A; Labianca R; Di Costanzo F; Secondino S; Crucitta E; Apolloni F; Del Santo A; Siena S
J Clin Oncol; 2008 Apr; 26(10):1619-25. PubMed ID: 18375891
[TBL] [Abstract][Full Text] [Related]
6. Comparison of darbepoetin alfa dosed weekly (QW) vs. extended dosing schedule (EDS) in the treatment of anemia in patients receiving multicycle chemotherapy in a randomized, phase 2, open-label trial.
Schwartzberg L; Burkes R; Mirtsching B; Rearden T; Silberstein P; Yee L; Inamoto A; Lillie T
BMC Cancer; 2010 Oct; 10():581. PubMed ID: 20973982
[TBL] [Abstract][Full Text] [Related]
7. The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agents.
Mhaskar R; Wao H; Miladinovic B; Kumar A; Djulbegovic B
Cochrane Database Syst Rev; 2016 Feb; 2(2):CD009624. PubMed ID: 26845108
[TBL] [Abstract][Full Text] [Related]
8. Use of erythropoiesis-stimulating agents among chemotherapy patients with hemoglobin exceeding 12 grams per deciliter.
Nordstrom BL; Luo W; Fraeman K; Whyte JL; Nordyke RJ
J Manag Care Pharm; 2008; 14(9):858-69. PubMed ID: 19006442
[TBL] [Abstract][Full Text] [Related]
9. Darbepoetin alfa 300 or 500 μg once every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia.
Auerbach M; Silberstein PT; Webb RT; Averyanova S; Ciuleanu TE; Shao J; Bridges K
Am J Hematol; 2010 Sep; 85(9):655-63. PubMed ID: 20661916
[TBL] [Abstract][Full Text] [Related]
10. Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level < 10 g/dL versus > or = 10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trial.
Vansteenkiste J; Hedenus M; Gascon P; Bokemeyer C; Ludwig H; Vermorken J; Hamilton L; Bridges K; Pujol B
BMC Cancer; 2009 Sep; 9():311. PubMed ID: 19728887
[TBL] [Abstract][Full Text] [Related]
11. A randomized comparison of once weekly epoetin alfa to extended schedule epoetin or darbepoetin in chemotherapy-associated anemia.
Steensma DP; Dakhil SR; Novotny PJ; Sloan JA; Johnson DB; Anderson DM; Mattar BI; Moore DF; Nikcevich D; Loprinzi CL
Am J Hematol; 2015 Oct; 90(10):877-81. PubMed ID: 26149465
[TBL] [Abstract][Full Text] [Related]
12. A prospective observational study of the effectiveness, safety, and effect on fatigue of darbepoetin alfa for the treatment of chemotherapy-induced anaemia.
Mel JR; Salar A; Rodríguez CA; Alegre A; González A; Cassinello J; Montesinos J; Gasquet JA; Sánchez J; Saigí E;
Curr Med Res Opin; 2008 Oct; 24(10):2931-42. PubMed ID: 18775103
[TBL] [Abstract][Full Text] [Related]
13. Transfusion risk in cancer patients with chemotherapy-induced anemia when initiating darbepoetin alfa therapy at a baseline hemoglobin level of <9 g/dL versus 9 to <10 g/dL versus ≥ 10 g/dL: an exploratory analysis of a phase 3 trial.
Canon JL; Vansteenkiste J; Hedenus M; Gascon P; Bokemeyer C; Ludwig H; Vermorken J; Legg J; Pujol B; Bridges K
Med Oncol; 2012 Sep; 29(3):2291-9. PubMed ID: 22081263
[TBL] [Abstract][Full Text] [Related]
14. A multicenter retrospective cohort study of practice patterns and clinical outcomes of the use of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia.
Schwartzberg L; Shiffman R; Tomita D; Stolshek B; Rossi G; Adamson R
Clin Ther; 2003 Nov; 25(11):2781-96. PubMed ID: 14693304
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy-induced anemia at an urban academic medical center: iron studies and supplementation.
Shord SS; Cuellar S
J Am Pharm Assoc (2003); 2008; 48(4):487-93. PubMed ID: 18653424
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia.
Pashos CL; Larholt K; Fraser KA; McKenzie RS; Senbetta M; Piech CT
Support Care Cancer; 2012 Jan; 20(1):159-65. PubMed ID: 21359879
[TBL] [Abstract][Full Text] [Related]
17. Darbepoetin alfa administered every three weeks (Q3W) in anemic cancer patients receiving chemotherapy (CT).
Martelli O; Garassino M; Sacchetta S; Caristo R; Zivi A; Cerbone L; Mancuso A
Anticancer Res; 2008; 28(3B):1767-71. PubMed ID: 18630457
[TBL] [Abstract][Full Text] [Related]
18. A randomized, open-label, multicenter trial of immediate versus delayed intervention with darbepoetin alfa for chemotherapy-induced anemia.
Charu V; Saidman B; Ben-Jacob A; Justice GR; Maniam AS; Tomita D; Rossi G; Rearden T; Glaspy J
Oncologist; 2007 Oct; 12(10):1253-63. PubMed ID: 17962619
[TBL] [Abstract][Full Text] [Related]
19. An open-label study of darbepoetin alfa administered once monthly for the maintenance of haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis.
Agarwal AK; Silver MR; Reed JE; Dhingra RK; Liu W; Varma N; Stehman-Breen C
J Intern Med; 2006 Dec; 260(6):577-85. PubMed ID: 17116009
[TBL] [Abstract][Full Text] [Related]
20. Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial.
; Glaspy J; Vadhan-Raj S; Patel R; Bosserman L; Hu E; Lloyd RE; Boccia RV; Tomita D; Rossi G
J Clin Oncol; 2006 May; 24(15):2290-7. PubMed ID: 16710026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
